Evidence map›Paper›PMID 31491971›Full record

ArticleMetabolites2019

Oxylipin Profiling of Alzheimer's Disease in Nondiabetic and Type 2 Diabetic Elderly.

Jill K Morris, Brian D Piccolo, Casey S John, Zachary D Green, John P Thyfault, Sean H Adams

Abstract read
In one paragraph

Article in Metabolites, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 19 papers.

0numbers the graph read from it
0cells of the map it votes in
19citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

19 citing papers in PubMed.

  1. Trial
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Eicosanoid profiles in an arthritis model: Effects of a soluble epoxide hydrolase inhibitor.Biochimica et biophysica acta. Molecular and cell biology of lipids · 2024
    Article
  8. Article
  9. Article
  10. Article
  11. Review
  12. Article
  13. Soluble Epoxide Hydrolase and Diabetes Complications.International journal of molecular sciences · 2022
    Review
  14. Article
  15. Potential biomarkers identified in plasma of patients with gestational diabetes mellitus.Metabolomics : Official journal of the Metabolomic Society · 2021
    Article
  16. Review
  17. Article
  18. Article
  19. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Jill K MorrisDepartment of Neurology, University of Kansas Alzheimer's Disease Center, Kansas City, KS 66205, USA. jmorris2@kumc.edu.ORCID 0000-0001-5911-4190
Brian D PiccoloArkansas Children's Nutrition Center, Little Rock, AR 72205, USA. BDpiccolo@uams.edu.ORCID 0000-0002-1789-4587
Casey S JohnDepartment of Neurology, University of Kansas Alzheimer's Disease Center, Kansas City, KS 66205, USA. cjohn@kumc.edu.
Zachary D GreenUniversity of Kansas Alzheimer's Disease Center, Fairway, KS 66205, USA. zgreen@kumc.edu.
John P ThyfaultDepartment of Molecular and Integrative Physiology, University of Kansas, Kansas City, KS 66045, USA. jthyfault@kumc.edu.ORCID 0000-0001-7920-7466
Sean H AdamsArkansas Children's Nutrition Center, Little Rock, AR 72205, USA. SHAdams@uams.edu.

Funding

UNM HSC Clinical and Translational Science CenterUL1TR001449 · NCATS · UNIVERSITY OF NEW MEXICO HEALTH SCIS CTR · PI CAMPEN, MATTHEW J, PANDHI, NANCY · 2015 to 2024
$36.9M
Translational Regulation in Normal Erythropoiesis and Diamond Blackfan AnemiaP20GM121293 · NIGMS · ARKANSAS CHILDREN'S HOSPITAL RES INST · PI Samrat Roy Choudhury · 2017 to 2026
$27.6M
University of Kansas Alzheimer's Disease Research Center (KU ADRC)P30AG072973 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI Jaime Perales Puchalt · 2021 to 2026
$25.3M
University of Kansas Alzheimer's Disease Core CentersP30AG035982 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BROOKS, WILLIAM M. · 2011 to 2020
$16.6M
Heartland Institute for Clinical and Translational ResearchUL1TR000001 · NCATS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI BAROHN, RICHARD J. · 2012 to 2015
$13.0M
West Coast Central Comprehensive Metabolomics Resource Core (WC3MRC)U24DK097154 · NIDDK · UNIVERSITY OF CALIFORNIA AT DAVIS · PI FIEHN, OLIVER · 2012 to 2017
$9.9M
Statins: Mitochondrial Function and Aerobic CapacityR01AR071263 · NIAMS · UNIVERSITY OF KANSAS MEDICAL CENTER · PI NEUFER, P DARRELL, THYFAULT, JOHN P · 2017 to 2021
$3.0M
Relationship of Energetics and Cognitive Trajectory’R00AG050490 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI MORRIS, JILL KATHLEEN · 2018 to 2020
$747k
Skeletal muscle mitochondrial abnormalities in Alzheimer's DiseaseR21AG056062 · NIA · UNIVERSITY OF KANSAS MEDICAL CENTER · PI THYFAULT, JOHN P · 2017 to 2018
$421k
Sexual dimorphism, hepatic mitochondrial adaptations, and hepatic steatosisI01BX002567 · VA · KANSAS CITY VA MEDICAL CENTER · PI THYFAULT, JOHN P · 2015 to 2025
–
BLRD VA I01 BX002567NCATS NIH HHS UL1 TR000001NCATS NIH HHS UL1-TR-000001NCATS NIH HHS UL1 TR001449NCATS NIH HHS UL1-TR-001449NIAMS NIH HHS R01 AR071263NIA NIH HHS P30 AG035982NIA NIH HHS P30-AG-035982NIA NIH HHS P30 AG072973NIA NIH HHS R00 AG050490NIA NIH HHS R00-AG-050490NIA NIH HHS R21 AG056062NIA NIH HHS R21-AG-056062NIDDK NIH HHS U24 DK097154NIGMS NIH HHS P20 GM121293NIH HHS P20-GM-121293NIH HHS R01 AR071263
6 · The paper itself

Abstract

Oxygenated lipids, called "oxylipins," serve a variety of important signaling roles within the cell. Oxylipins have been linked to inflammation and vascular function, and blood patterns have been shown to differ in type 2 diabetes (T2D). Because these factors (inflammation, vascular function, diabetes) are also associated with Alzheimer's disease (AD) risk, we set out to characterize the serum oxylipin profile in elderly and AD subjects to understand if there are shared patterns between AD and T2D. We obtained serum from 126 well-characterized, overnight-fasted elderly individuals who underwent a stringent cognitive evaluation and were determined to be cognitively healthy or AD. Because the oxylipin profile may also be influenced by T2D, we assessed nondiabetic and T2D subjects separately. Within nondiabetic individuals, cognitively healthy subjects had higher levels of the nitrolipid 10-nitrooleate (16.8% higher) compared to AD subjects. AD subjects had higher levels of all four dihydroxyeicosatrienoic acid (DiHETrE) species: 14,15-DiHETrE (18% higher), 11,12 DiHETrE (18% higher), 8,9-DiHETrE (23% higher), and 5,6-DiHETrE (15% higher). Within T2D participants, we observed elevations in 14,15-dihydroxyeicosa-5,8,11-trienoic acid (14,15-DiHETE; 66% higher), 17,18-dihydroxyeicosa-5,8,11,14-tetraenoic acid (17,18-DiHETE; 29% higher) and 17-hydroxy-4,7,10,13,15,19-docosahexaenoic acid (17-HDoHE; 105% higher) and summed fatty acid diols (85% higher) in subjects with AD compared to cognitively healthy elderly, with no differences in the DiHETrE species between groups. Although these effects were no longer significant following stringent adjustment for multiple comparisons, the consistent effects on groups of molecules with similar physiological roles, as well as clear differences in the AD-related profiles within nondiabetic and T2D individuals, warrant further research into these molecules in the context of AD.

Indexed as

alzheimer’s diseasedihetreoxylipintype 2 diabetes

Identifiers

PMID31491971
PMCPMC6780570

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.